title: Surgery of female genital tract tumour lung metastases.
abstract: BACKGROUND
  Lung metastases originating from tumours of the female genital tract are rare. Due to this rarity and their variable histology, it has been difficult to compare different patient series.
  
  
  METHODS
  A retrospective study of patients undergoing resection of lung metastases of female genital tract tumours (uterine and cervical cancer) during the period 01/01/1989 to 12/31/2006. Epidemiological, diagnostic and treatment data were collected. Non-parametric tests and survival analysis were performed using the Kaplan-Meier and log-rank test.
  
  
  RESULTS
  A resection was performed on 27 patients during the study period. Disease-free interval (DFI) from initial diagnosis of lung metastases was 58 months (1-195 months). The median survival from diagnosis of metastases was 94 months. The overall survival at 5 years after diagnosis of metastasis was 84.1%. A second surgery of metastases was performed on 5 patients (18.5%). Survival after second surgery of metastases: 80.5 months. Survival from diagnosis of metastasis at five years: endometrial carcinoma 100%, cervical cancer 62.5%, uterine sarcoma 60%. Adjuvant hormonal therapy was prescribed in 15 out of 16 patients with endometrial carcinoma. There was a statistically significant difference in the survival depending on the histological type and disease free interval.
  
  
  CONCLUSIONS
  Surgical treatment of lung metastases originating from female genital tract tumours (mainly endometrial carcinoma) is associated with a high long-term survival.
authors.affiliation: Servicio de Cirugía Torácica, Hospital General Universitario Gregorio Marañón, Madrid, España. ggcasaurran@gmail.com
authors.forename: Guillermo
authors.initials: G
authors.lastname: González Casaurrán
authors.forename: Carlos
authors.initials: C
authors.lastname: Simón Adiego
authors.forename: Rafael
authors.initials: R
authors.lastname: Peñalver Pascual
authors.forename: Nicolás
authors.initials: N
authors.lastname: Moreno Mata
authors.forename: Miguel Ángel
authors.initials: MÁ
authors.lastname: Lozano Barriuso
authors.forename: Federico
authors.initials: F
authors.lastname: González Aragoneses
mesh_terms: D000328:Adult; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy / Q000401:mortality / Q000556:secondary* / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000556:secondary / Q000601:surgery; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000556:secondary* / Q000601:surgery*; D008197:Lymph Node Excision; D008875:Middle Aged; D011013:Pneumonectomy / Q000379:methods*; D012086:Reoperation; D012189:Retrospective Studies; D012509:Sarcoma / Q000188:drug therapy / Q000401:mortality / Q000556:secondary* / Q000601:surgery*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000473:pathology*; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000473:pathology*
chemical_list: D018931:Antineoplastic Agents, Hormonal